CD8A and cancer: Moreover, it was subsequently shown that treatment with SVN-2B triggered a dense infiltration of CD8+ T cells in some patient lesions and a high rate of programmed cell death ligand 1 (PD-L1) expression in cancer cells, indicating emergence of resistance against CTL attack [181].